Up­dat­ed: Ab­b­Vie leaves some on­col­o­gy pro­grams out of 2023 pipeline high­lights

In an in­vestor up­date Thurs­day morn­ing, Ab­b­Vie left eight pro­grams out of its pipeline high­lights it shared with in­vestors, as com­pared to what ex­ists on the R&D page of its web­site, last re­freshed in De­cem­ber.

A Phase III study of Rin­voq in Takaya­su ar­teri­tis, a rare group of dis­or­ders in which blood ves­sels be­come in­flamed, was not in­clud­ed. The JAK in­hibitor is ap­proved for in­di­ca­tions like rheuma­toid arthri­tis and car­ries with it a black box warn­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.